These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38916237)

  • 1. Epicardial adipose tissue and residual cardiovascular risk: a comprehensive case analysis and therapeutic insights with Liraglutide.
    Cacciapuoti F; Mauro C; D'Andrea D; Capone V; Liguori C; Cacciapuoti F
    J Cardiovasc Med (Hagerstown); 2024 Aug; 25(8):637-641. PubMed ID: 38916237
    [No Abstract]   [Full Text] [Related]  

  • 2. The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes.
    Zhao N; Wang X; Wang Y; Yao J; Shi C; Du J; Bai R
    J Diabetes Res; 2021; 2021():5578216. PubMed ID: 34825006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide causes large and rapid epicardial fat reduction.
    Iacobellis G; Mohseni M; Bianco SD; Banga PK
    Obesity (Silver Spring); 2017 Feb; 25(2):311-316. PubMed ID: 28124506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
    van Eyk HJ; Paiman EHM; Bizino MB; de Heer P; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Smit JWA; Lamb HJ; Rensen PCN; Jazet IM
    Cardiovasc Diabetol; 2019 Jul; 18(1):87. PubMed ID: 31288820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
    Verma S; Bhatt DL; Bain SC; Buse JB; Mann JFE; Marso SP; Nauck MA; Poulter NR; Pratley RE; Zinman B; Michelsen MM; Monk Fries T; Rasmussen S; Leiter LA;
    Circulation; 2018 May; 137(20):2179-2183. PubMed ID: 29760228
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.
    Manubolu VS; Lakshmanan S; Kinninger A; Ahmad K; Susarla S; Seok HJ; Hamal S; Dahal S; Roy SK; Budoff MJ
    J Am Coll Cardiol; 2024 Aug; 84(9):865-867. PubMed ID: 39168573
    [No Abstract]   [Full Text] [Related]  

  • 7. Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
    Guthrie R
    Postgrad Med; 2018 Mar; 130(2):154-158. PubMed ID: 29350569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide and cardiovascular outcomes in type 2 diabetes.
    Jones B
    Ann Clin Biochem; 2016 Nov; 53(6):712. PubMed ID: 28071177
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.
    Gilbert MP; Bain SC; Franek E; Jodar-Gimeno E; Nauck MA; Pratley R; Réa RR; Kerr Saraiva JF; Rasmussen S; Tornøe K; von Scholten BJ; Buse JB;
    Ann Intern Med; 2019 Mar; 170(6):423-426. PubMed ID: 30508430
    [No Abstract]   [Full Text] [Related]  

  • 10. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ;
    N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
    Olšovský J
    Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ
    Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular Effects of Liraglutide.
    Mikhail N
    Curr Hypertens Rev; 2019; 15(1):64-69. PubMed ID: 29737256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
    Buse JB; Bain SC; Mann JFE; Nauck MA; Nissen SE; Pocock S; Poulter NR; Pratley RE; Linder M; Monk Fries T; Ørsted DD; Zinman B;
    Diabetes Care; 2020 Jul; 43(7):1546-1552. PubMed ID: 32366578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.
    Kim HJ; Kim DJ
    J Diabetes Investig; 2017 Jul; 8(4):431-433. PubMed ID: 27930863
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
    Petit JM; Cercueil JP; Loffroy R; Denimal D; Bouillet B; Fourmont C; Chevallier O; Duvillard L; Vergès B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):407-415. PubMed ID: 27732328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
    Marso SP; Baeres FMM; Bain SC; Goldman B; Husain M; Nauck MA; Poulter NR; Pratley RE; Thomsen AB; Buse JB;
    J Am Coll Cardiol; 2020 Mar; 75(10):1128-1141. PubMed ID: 32164886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
    Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
    [No Abstract]   [Full Text] [Related]  

  • 20. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.
    Dutour A; Abdesselam I; Ancel P; Kober F; Mrad G; Darmon P; Ronsin O; Pradel V; Lesavre N; Martin JC; Jacquier A; Lefur Y; Bernard M; Gaborit B
    Diabetes Obes Metab; 2016 Sep; 18(9):882-91. PubMed ID: 27106272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.